British drugmaker Shire ( SHPGY) said its second-quarter product revenue rose 7% year over year, led by growth in its biggest seller, Adderall XR. Product sales for the quarter climbed to $376 million from $351.6 million in the same period a year ago. Adderall XR, a treatment for attention deficit hyperactivity disorder, accounted for $220.7 million of sales in the latest quarter. Total revenue advanced 3% to $439.1 million from $424.6 million and was essentially in line with Wall Street's expectations. Earnings declined to $61.3 million from $109.9 million. Shire had a profit of 12 cents per ordinary share in the second quarter and earnings of 36 cents per American depositary share. Excluding items, the company would have earned around 15 cents per ordinary share and 44 cents per ADS. On that basis, Shire topped the consensus Thomson Financial estimate by 6 cents. "Shire continues to deliver in line with our expectations and we're making good progress with our pipeline," Matthew Emmens, the chief executive, said in a statement Friday. Additionally, Shire reiterated its previously stated guidance of revenue growth for 2006 to be in the low double-digit range. Earnings for this year will be affected by the costs associated with the continued development and launch of five new products, Shire said. Shire's American depositary shares were gaining 25 cents, or 0.5%, to $47.12.